Data from Lundbeck’s Phase 2 and 3 clinical trials of idalopirdine in Alzheimer’s patients, will be made available to researchers worldwide through the Critical Path for Alzheimer’s Disease (CPAD) consortium database,…
Axsome Therapeutics is planning to complete its ADVANCE-1 clinical trial, evaluating AXS-05 as a treatment for agitation in Alzheimer’s disease, a few months earlier to ensure the safety of study participants during the COVID-19 pandemic. Top-line results from this Phase 2/3 trial, which opened in 2017, are now expected…
Because the COVID-19 pandemic has many people staying at home, the Alzheimer’s Foundation of America (AFA) has suggestions about activities to help patients and their families stay active and engaged. “Stimulating the brain is beneficial both for individuals living with Alzheimer’s disease…
Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance related to the COVID-19 pandemic. A Phase 2 study of people with dementia linked to Parkinson’s disease is…
A new analysis of data from a Phase 3 clinical trial testing the blood pressure medication nilvadipine supports evidence that its use helps to slow cognitive decline in Alzheimer’s patients with very mild, very early stage disease. This finding was reported…
Moderate lifetime alcohol intake in middle-aged and older people who don’t show signs of dementia is associated with lower deposits of amyloid-beta, the protein that forms toxic aggregates in the brain and is thought to be involved in the onset of Alzheimer’s disease, a study from Korea found.
Giving Dantrium (dantrolene) through the nose rather than by mouth may maximize its neuroprotective properties in treating conditions like Alzheimer’s disease, a new study suggests. The study, “Intranasal administration of dantrolene increased brain…
An Alzheimer’s Association survey of primary care physicians found that while 87% expect the number of dementia patients to rise within the next five years, half say the U.S. health system is unprepared for the increased burden. The annual report, “Alzheimer’s Disease Facts and Figures,” provides…
Dietary supplements with the amino acid L-serine may help reduce memory loss associated with Alzheimer’s disease, a new study suggests. That result was described in the study “Impairment of Glycolysis-Derived L-Serine…
A specific chemical alteration present in the presenilin1 (PSEN1) gene may be a biomarker for earlier Alzheimer’s disease (AD) diagnosis and treatment response monitoring, a study suggests. The modification, called DNA methylation, was observed both in brain samples of Alzheimer’s mouse models and post-mortem brain tissue of…
Get regular updates to your inbox.